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Abstract: Coagulase-negative staphylococci (CNS) are a heterogenous group of Gram-positive 
cocci that are widespread commensals among mammalia. Unlike their coagulase-positive 
counterpart, Staphylococcus aureus, CNS produce few virulence patterns and normally refrain 
from invading tissue. Yet, not only can CNS cause infections in normal host tissue, but modern 
medicine has also seen their rise as opportunists that display adherence to medical device materi-
als to produce a protective bioﬁ  lm. CNS have historically been more resistant to antimicrobials, 
including the β-lactam antibiotics, than S. aureus and some hospitals reveal rates of oxacillin 
resistance in CNS approaching 90%. Cross resistance to non-β-lactam agents has been a recurrent 
theme over the past 40 years in the CNS. Thus, there has been a pressing need for newer antimi-
crobial agents with good antistaphylococcal activity. Those new agents tend to have excellent 
antistaphylococcal activity include daptomycin, linezolid, oritavancin, telavancin, tigecycline, 
dalbavancin, new quinolones, and ceftibiprole, several of which have unique mechanisms of 
action. The MIC90 for these new compounds typically ranges from 0.5–4 µg/mL. Staphylococcal 
bioﬁ  lm formation is quite common in CNS infections and markedly increases the MIC for most 
older antimicrobials. Several of the newer agents offer some promise of penetration of bioﬁ  lm 
to inhibit or kill adherent staphylococci. CNS will likely remain a major cause of infections in 
the modern age, evolve further antimicrobial resistance mechanisms, and require development 
of newer antimicrobials for curative therapy.
Keywords: coagulase-negative staphylococcus, Staphylococcus epidermidis, Staphylococcus 
haemolyticus, Staphylococcus lugdenesis, bioﬁ  lm, new antibiotics, antibiotic resistance
Introduction
The group of Gram-positive bacteria identiﬁ  ed as coagulase-negative staphylococci 
(CNS), usually harmless commensals, have become important, commonly isolated 
pathogens in clinical microbiology laboratories around the world (Kloos and 
Bannerman 1994; Cerca et al 2005; Arciola et al 2006; Bayram and Balci 2006; 
Caierão et al 2006; Widerström et al 2006). Over the last several decades, infection 
with CNS has been characterized as related to “medical progress” (Rupp and Archer 
1994). Accordingly, CNS, as human pathogens, are usually associated with healthcare 
settings and occur in patients who are immunocompromised or harboring indwelling 
polymer or metallic devices (Bisno 1995).
By 1985, there were 19 recognized species of CNS, 8 of which exhibited a pos-
sible association with human infection (Kloos and Jorgensen 1985). At that time, the 
most commonly isolated of these pathogenic species were Staphylococcus epider-
midis and S. haemolyticus. Typing of CNS in the late 1980s was primarily based on 
biochemical testing proﬁ  les such as the one proposed by Kloos and Schleifer in 1975 
(Kloos and Schleifer 1975). This scheme used certain biochemical markers including 
novobiocin resistance; fermentation of: sucrose, fructose, galactose, ribose, lactose, Therapeutics and Clinical Risk Management 2007:3(6) 1144
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turanose, melezitose, xylose, mannose, trehalose, mannitol, 
xylitol, and maltose; and phosphatase nitrate reduction and 
use of arginine. With character types deﬁ  ned through major 
and minor biochemical routes, a simpliﬁ  ed scheme emerged 
for speciating staphylococci of human origin (Kloos and 
Schleifer 1975).
Other early speciation methods included antimicrobial 
susceptibility proﬁ  le typing, multilocus enzyme electropho-
resis, and cellular fatty acid analysis (Birnbaum et al 1991). 
Due to the intensive labor involved in all of these early typing 
schemes and because of the assumption of the low virulence 
of this group of organisms, most isolates with morphology 
of Gram-positive cocci in clusters and positive for catalase 
production without coagulase production were described 
simply as CNS. Clinical debate continued about the clinical or 
therapeutic utility of speciating CNS; nevertheless, evidence 
emerged suggesting that particular species of CNS may be 
associated with speciﬁ  c diseases, readdressing the question 
of a need for speciation (Kloos and Bannerman 1994).
In the US, bacteremia due to unspeciated CNS have 
increased from 9% to 27% from 1980 to 1989 (Schaberg 
et al 1991). Over the last decade, the numbers of CNS species 
have grown to total 32, with half of these species isolated 
from human tissue and blood samples (von Eiff et al 2002). 
Consequently, development of commercial automated sys-
tems such as the Microscan Pos ID, Rapid Pos ID (Baxter 
Diagnostic Inc., MicroScan Division, West Sacramento, CA, 
USA), and VITEK (bioMérieux Vitek Inc., Hazelwood, MO, 
USA) have facilitated more rapid testing of staphylococci by 
using computer software to analyze combined biochemical 
and antibiotic susceptibility proﬁ  les (Kloos and George 1991; 
Hussain et al 1998; Caierão et al 2006). These robotic sys-
tems scan incubated trays using ﬂ  uorimetric and photometric 
readings to record ﬂ  ouresence, turbidity, and colormetric 
signals which indicate relative growth in each well (Ligozzi 
et al 2002).
Each automated system uses a unique set of biochemical 
tests and species parameters. Small differences in identiﬁ  ca-
tion methods, however, have the potential to cause inconsis-
tencies in results when comparing one system’s speciation 
of a microbial isolate to another (Perl et al 1994). Moreover, 
automated systems can cause outright misidentiﬁ  cation even 
at the genus level. In one report, results from an automated 
typing system were compared to those of a 16s rRNA specia-
tion for 19 clinical bacterial isolates (Ben-Ami et al 2005). 
The automated system identiﬁ  ed all of the isolates as Kocuria, 
while the 16s rRNA sequence subsequently identiﬁ  ed all 19 
isolates as CNS, 18 S. epidermidis and 1 S. hamolyticus; nev-
ertheless, the automated identiﬁ  cation of CNS at the levels of 
species and subspecies presents potential value for clinical 
correlation and therapeutic intervention (Rupp and Archer 
1994). Other work recently presented suggests S. epidermidis 
isolates may be misidentiﬁ  ed even as S. auricularis, so it 
is clear that erroneous typing could delay appropriate and 
necessary therapeutic intervention (John et al 2006).
Regardless of species specificity, treatment of CNS 
infection has become increasingly difﬁ  cult due to the high 
prevalence of antibiotic-resistant strains. Widely used anti-
biotics including penicillins, particularly semi-synthetic 
penicillins, cephalosporins, macrolides, aminoglycosides, 
and tetracyclines, have proven to be ineffective in inhibit-
ing several prevalent species of CNS, thus, augmenting the 
need for new and effective antimicrobials (Cerca et al 2005; 
Gaudioso de Allori et al 2006; Arciola et al 2006). To add 
to the resistance problem, multi resistance in CNS, as in 
S. aureus, is carried out on a staphylococcal chromosome 
cassette (SCC) which almost always includes the mecA 
gene for resistance to semi-synthetic penicillins (SCCmec) 
(Hanssen et al 2004). SCCmec resides in the chromosome 
as several cassette variants I-V .
CNS are ubiquitous in nature, residing on skin and 
mucous membranes (Costa et al 2004). When exposed to 
medical devices, the CNS anchor themselves to a polymer 
surface via van der Waal’s forces, hydrophobic interactions, 
and polarity, ultimately forming a thick bioﬁ  lm (Vuong et al 
2003; Mack et al 2006). Production of bioﬁ  lm reduces the 
organism’s susceptibility to speciﬁ  c antimicrobials which 
Table 1 Coagulase-negative staphylococci reported to cause 
infections in humans1
Species  Common site/type of infection
S. capitis  Urinary tract, skin, blood, CSF 
 shunt
S. caprae  Urinary tract, blood, access sites, 
 prosthetic  joints
S. cohnii  Wounds, joints, meninges
S. epidermidis  Widespread sites; wounds, access 
 devices
S. haemolyticus  Native valve, wound, bone, and joint
S. hominis  Blood, lung, breast
S. lugdunensis  Endothelium, heart valves
S. pasteurii Orthopedic  implants
S. saprophiticus Urinary  tract
S. scheiferi  Nosocomial infections, CSF shunts, 
 pacemakers
S. warneri  Widespread sites; neonatal intensive
 care  units
S. xylosus Blood
1Derived from Tristan et al (2006) and Koksal et al (2007).Therapeutics and Clinical Risk Management 2007:3(6) 1145
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are highly active against planktonic cultures. The problem of 
antibiotic bioﬁ  lm interaction has recently become a stimulus 
to develop antibiotics that can inhibit initial microbial adhe-
sion to polymer surfaces as well as growth on planktonic 
cultures (Cerca et al 2005).
In this paper we will review the general problem of 
antibiotic resistance in CNS and discuss the susceptibility 
and resistance, where data are available, for speciﬁ  c species. 
Additionally, in view of a recent expansion in new anti 
staphylococcal agents, we will address the susceptibility 
proﬁ  les of some of these newer agents.
Pre-1994 susceptibility literature
Antimicrobial susceptibility in CNS became an issue in 
the 1970s when these species were isolated as pathogens 
in prosthetic valve endocarditis infections of cerebrospinal 
ﬂ  uid shunt infections (Keys and Hewitt 1973; Shoenbaum 
et al 1975). There were earlier harbingers that new resistance 
genes were emerging, speciﬁ  cally those whose products 
would inhibit the binding of semisynthetic penicillins, agents 
that had been developed to resist the effects of extracellular 
staphylococcal β-lactamases. Methicillin was the predomi-
nant semisynthetic penicillin used in early therapy so the 
term “methicillin resistance” became a generic term for resis-
tance to β-lactam antibiotics based on the inability of these 
agents to bind to the new penicillin-binding protein product 
of mecA, PBP-2a (Sutherland and Rollison 1964; Bentley 
et al 1967). During the 1970s it became clear that methicil-
lin resistance was more prevalent in CNS (MRCNS) than in 
methicillin-resistant S. aureus (MRSA), an observation that 
continues to be true today.
During the 1970s and early 1980s, the problem of multi-
resistance in CNS was reported primarily in cases of device 
related infections particularly prosthetic valve endocarditis 
(Archer 1978). In a group of S. epidermidis associated with 
device infections, 56% were resistant to methicillin and 70% 
were resistant to cefoxitin and cephardine (Archer 1978). 
For the subsequent period through 1994, Archer and Climo 
have reviewed the literature (Archer and Climo 1994) in 
which they report an escalation of resistance for almost all 
antimicrobial classes excluding glycopeptides: β-lactams 
aminoglycosides, trimethoprim, rifampin, ﬂ  uoroquinolones, 
macrolides, and tetracyclines. Therefore, in this current paper 
we will review the post-1994 literature on the subject.
Post-1994 susceptibility literature
The trends in resistance in CNS over the last 13 years have 
continued to show escalation in the frequency and expression 
of resistance determinants. Resistance to β-lactam agents 
(methicillin resistance) has remained the foremost strain 
determinant. Strains of MRCNS are often linked to multi-
resistance, like their MRSA counterparts, thus presenting 
an ongoing therapeutic challenge. The discovery of speciﬁ  c 
chromosomal cassettes carrying the mecA gene as well as 
multiple other genes has provided a new backdrop against 
which evolution of CNS species and their respective SCCmec 
can be measured (Mongkolrattanothai et al 2004; Noto and 
Archer 2006). A dichotomy between methicillin-susceptible 
CNS (MSCNS) and MRCNS permeates the literature on 
susceptibility testing. In fact, these groups are usually tested 
and reported separately. For example the analysis of US key 
bloodstream bacterial isolates from 1995, 1996, and 1997 
showed that among 43,789 CNS, 42% were MSCNS and 
58% were MRCNS (Sahm et al 1999). Moreover, in this 
group of MRCNS the rate of vancomycin minimum inhibi-
tory concentration (MIC) of 4 µg/mL increased from 1.8% 
to 4.8% from 1995 to 1997.
That database, SENTRY, was expanded to other countries 
during 1997–1999 (Diekema 2001). Interestingly, while 
rates of methicillin resistance among CNS varied widely 
among 13 European countries, the rate was around 70% for 
5 global locations; Canada, USA, Latin America, Europe, 
and the West Pacific. Co-resistance patterns were also 
reported for the ﬁ  ve regions based on oxacillin resistance. For 
example in the US trimethoprim-sulfamethoxazole (SXT) 
resistance was about 17% in MSCNS compared with nearly 
57% in MRCNS. Similar trends were seen for gentamicin, 
Table 2 List of antimicrobial classes potentially active against 
coagulase-negative staphylococci
Class
Aminoglycosides
Carbapenems
Cephalosporins
Choramphemicols
Diaminopyrimidines
Fluoroquinolones
Fusidic acid
Glycopeptides
Lincomycins
Lipopeptides
Macrolides
Oxazolidinones
Polymyxins
Rifampicins
Semi-synthetic penicillins
Sulfonamides
Tetracyclines 
Dihydrofolate reductase inhibitors (trimethoprim)Therapeutics and Clinical Risk Management 2007:3(6) 1146
John and Harvin
ciproﬂ  oxacin, clindamycin, and erythromycin both in US and 
global sites (Diekema et al 2001). For most antimicrobials, 
intensive care units (ICUs) tend to show the highest rates of 
antimicrobial resistance (Fridkin et al 1999). In a massive 
study to determine the focus of antibiotic resistance in dif-
ferent areas for over 80 hospitals, the rates of MRCNS were 
signiﬁ  cantly higher in ICU – than in non-ICU patients and 
were higher in non-ICU patients than in outpatients. These 
data suggest that the major risk for MRCNS is associated 
with more complex hospital environments.
A similar large study was conducted in which staphy-
lococci were collected from 20 regional health centers in 
several countries across Europe, Asia, and Latin America 
(Sanches et al 2000). The CNS were divided into methicil-
lin-resistant S. epidermidis (MRSE), methicillin-resistant 
S. haemolyticus (MRSH), and other MRCNS and their 
susceptible counterparts. Cross resistance was most com-
mon in the methicillin-resistant groups. For example, 
rates of SXT, ciproﬂ  oxacin, and gentamicin were 64%, 
50.5%, and 72.3% respectively. MRSH showed even 
higher frequencies of cross resistance. These trends in 
cross resistance among CNS were different than those for 
MRSA, suggesting that different selection pressures are at 
work for the two groups.
Another study tested susceptibility of only skin and 
soft tissue isolates in 283 US hospitals and 301 hospitals 
in Europe for 9 antimicrobials, including amoxicillin-
clavulanate, cefotaxime, cetriaxone, ciprofloxacin, 
erythromycin, gentamicin, levofloxacin, trimethoprim 
(TMP)/sulfamethoxazole (SMX), and vancomycin. For 
MSCNS almost all isolates were susceptible to amoxicillin-
clavulanate, suggesting that clavulanate remains very 
active against staphylococcal β-lactamase (Jones et al 
2003). For the ﬂ  uoroquinolones, ciproﬂ  oxacin averaged 
about 90% susceptibility and, where tested, levoﬂ  oxacin 
was active against slightly more strains. For example, 
in Italy 83.3% of isolates were susceptible to ciproﬂ  oxacin 
versus 85.7% for levoﬂ  oxacin. Ranges of activity for gen-
tamicin (86.1%–96.4%) and TMP/sulfamethizole (SMZ) 
(88.1%–92.7%) were active in a similar range. Over 25% of 
isolates were resistant to erythromycin whereas all isolates 
were susceptible to vancomycin. For MRCNS the resis-
tance trends were, in general, similar in European and US 
isolates with some exception. For example, ciproﬂ  oxacin 
resistance was 65.0%–66.7% across four European coun-
tries (France, Germany, Italy, and Spain) versus a range of 
38.1%–47.0% in the US. Gentamicin resistance was higher 
in Europe (range of 50.2%–61.3%) in the US (32.4%). No 
vancomycin resistance was detected.
Cuevas et al studied the trends of resistance in clinical 
isolates of CNS in Spain for ﬁ  ve periods from 1986 to 2002 
(Cuevas et al 2004). For all years together, 28% of strains were 
community in origin and 72% were nososcomial. Oxacillin 
resistance rose steadily from 32.5% in 1986 to 61.3% in 2002. 
Gentamicin resistance rates peaked in 1994 at 41.4% but 
dropped to 27.85% in 2002. Most interestingly, ciproﬂ  oxacin 
resistance rose from 1.1% in 1986 to 44.9% in 2002. Although 
there was no vancomycin resistance, there was one isolate 
in the 1996 study resistant to teichoplanin, an observation 
made earlier in one isolate of S. epidermidis from a corneal 
infection (Pinna et al 1999). Nosocomial strains were more 
likely to demonstrate resistance. In another study done in 
Uppsala, Sweden to determine more speciﬁ  cally how an ICU 
stay would inﬂ  uence CNS resistance, high rates of oxacillin 
Table 3 New agents with good antibacterial activity against coagulase-negative staphylococci
Agent  Year introduced  Mechanism of action  MIC90 CNS  MIC90 S. aureus Reference
     MSCNS/MRCNS  MSSA/MRSA 
Ceftibiprole  N.A.  Binds to abberant penicillin binding  1.0/2.0  0.5/2.0  Bogdanovich et al 2005a
   protein,PBP-2A
Daptomycin  2003  Cell membrane lysis  0.5/0.5  0.5/0.5  Critchley et al 2003
          Petersen et al 2002
Dalbavancin  N.A.  Blocks cell-wall synthesis like   0.06/0.06  0.06/0.06  Lin et al 2005
   teichoplanin
Linezolid  2000  Binds to tRNA  4.0/4.0  4.0/4.0  Noskin et al 1999
Moxiﬂ  oxacin  2002  Interferes with topoisomerase II and IV  0.12/4.0  0.12/4.0  Hardy et al 2000
Televancin N.A.  Blocks the synthesis of phospholipids in   0.5/1.0  0.5/0.5  King et al 2004
   cell  membranes
Tigecycline  2003  Blocks 30s ribosome  0.5/0.5  0.5/0.5  Frische et al 2004
          Gales et al 2005
          Sader et al 2005
Abbreviations: CNS, coagulase-negative staphylococci; MSCNS/MRCNS, methicillin-susceptible/methicillin-resistant CNS; MSSA/MRSA, methicillin-susceptible S. aureus/
methicillin-resistant S. aureus.Therapeutics and Clinical Risk Management 2007:3(6) 1147
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and ciproﬂ  oxacin resistance (92% and 83% respectively) in 
20 ICU patients were correlated with longer lengths of stay. 
Genotyping of the ICU CNS isolates found 32 pulse ﬁ  eld types 
involved, but 16 genotypes colonized more than 1 individual 
suggesting some clonality among these CNS isolates.
In a study from Greece of intravenous catheter infec-
tions associated with bacteremia, over a 2-year period CNS 
were responsible for nearly 60% of infections (Paragioudaki 
et al 2004). For these pathogens, in 1999, the resistance rate 
was 72% for ampicillin, oxacillin, ceftazidime, ceftriaxone, 
cefaclor, amoxicillin/clavulanate, and impenem, with slightly 
lower rates for SXT, ciproﬂ  oxacin, and amikacin. There 
was no vancomycin resistance. Rates dropped slightly in 
the year 2000 for the same antimicrobials. The redundancy 
of resistance rates may be due to spread of virulent CNS 
clones as was observed earlier at the University of Patras 
(Spiliopoulou et al 2003).
Several studies combined automated species identiﬁ  ca-
tion with antimicrobial susceptibility testing. From Italy, 
Ariciola et al reported resistance levels in 15 species of 
193 isolates found to colonize orthopedic implants (Arciola 
et al 2006). In the 5 most prevalent species – S. hominis, 
S. haemolyticus, S. capitis, S. warnerii, S. cohenii – resis-
tance to penicillin was similar (51%–66%). Most oxacillin 
resistance was seen in S. haemolyticus whereas no oxacillin 
resistance was present in S. warneri. Multiple antibiotic resis-
tance genes were most likely to be found in S. haemolyticus, 
averaging 2.8 for that species. Though the data are small in 
number, this study suggests that both careful susceptibility 
testing along with species identiﬁ  cation is helpful in certain 
device-related infections.
CNS remain the major cause of postcataract endophthal-
mitis. Recchia et al found that nearly 60% of pathogens from 
such cases were CNS and 91% of these were S. epidermidis 
(Recchia et al 2006). In analyzing 2 groups, for the 5 years 
before and after 1994, a signiﬁ  cant increase in resistance was 
seen for ciproﬂ  oxacin (20 to 38%) and cefazolin (19 to 40%). 
TMP/SMZ resistance stated relative stable, around 27%.
The study of device-related antimicrobial resistance has 
been hampered by lack of good models. Work with newer 
models has determined activity of various antibacterial 
solutions activity against different bacteria after adherence to 
silicone catheter segments (Sherertz et al 2006). Results showed 
that S. epidermidis was the most susceptible in terms of log kill 
over 24 hours to most antimicrobials tested and, in particular, 
to a complex solution of minocycline, EDTA, and ethanol.
New individual agents
Several new antimicrobials with good anti-staphylococcal 
activity have been marketed recently or will likely soon be 
marketed: ceftobiprole, dalbavancin, daptomycin, linezolide, 
tigecycline and telavancin. We will discuss the reports that 
have included CNS in the susceptibility proﬁ  le.
Linezolid
This oxazolidinone was introduced into clinical practice (in 
the US) in 2000. Its mechanism of action involves the binding 
of N-formylmethionyl-tRNA to the ribosome with the 50s 
subunit, but not the 30s subunit of the ribosome (Shinabarer 
1999). There are no comparative trials of linezolid therapy for 
CNS infections. With an MIC90 = 1–4 µg/mL, it has become 
a major option for therapy in resistant and recalcitrant staphy-
lococcal infections including those due to CNS (Davidson 
and Low 2004). In the largest in vitro experience as of its 1999 
publication, Noskin et al studied 365 oxacillin-susceptible 
and 441 oxcillin-resistant CNS (Noskin et al 1999). Both 
groups had the same MIC50 and MIC90, 2 and 4 µg/mL 
respectively. At that time, only vancomycin of the agents 
studied was more active. Data submitted for US registration 
of linezolid showed MIC90 values of both methicillin-resistant 
and methicillin-resistant S. epidermidis of 1–4 µg/mL (Pﬁ  zer 
data on ﬁ  le). Postmarketing surveillance programs reported 
for 870 CNS isolates an MIC90 of 1 µg/mL (Ross et al 2005). 
Only one isolate had an MIC  8 µg/mL.
In vitro development of resistance occurs very slowly 
with serial passage but when it does occur, it is related to 
two independently isolated point mutations at G2447U 
and G2576U of the 23S rRNA (Shinabarger 1999). Resis-
tance in the clinical setting, interestingly, has involved 
a report of linezolid-resistant CNS (Potoski et al 2006). 
The University of Pittsburgh Medical Center experienced 
this cluster of 25 linezolid-resistant CNS isolates with 
a single S. epidermidis clone, shown by pulse-ﬁ  eld gel 
Table 4 Ideal characteristics of anti-coagulase-negative 
staphylococcal antimicrobials
•  Ease of synthesis, isolation
•  Evidence that bactericidal concentration (MBC) closely 
  approaches the inhibitory concentrations (MIC)
•  Excellent extracellular and intracellular activity
•  Pharmacokinetics/pharmacodynamics favorable to long 
 intermittent  dosing
•  Prolonged post-antibiotic effect
• Good  bioﬁ  lm penetration 
• Potential  bioﬁ  lm inhibition
•  Lack of antagonism with other anti-staphylococcal agents
•  Slow evolution of in vitro and in vivo resistance
•  Low indices of systemic and organ toxicityTherapeutics and Clinical Risk Management 2007:3(6) 1148
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electrophoresis similarity, that infected 21 patients. The 
linezolid MIC was 256 µg/mL in 24 of the 25 isolates. 
In this group of patients, previous linezolid use was a risk 
factor for development of resistance.
Tigecycline
Tigecycline is a minocycline derivitative with excellent 
activity against resistant Gram-positive bacteria. A South 
American study analyzed 47 MSCNS and 180 MRCNS for 
tigecycline susceptibility (Gales et al 2005). Both groups 
displayed an MIC90 of 0.5 µg/mL (identical for S. aureus) 
and 100% were susceptible to 2 µg/mL. In a 2004 publica-
tion 321 MSCNS and 1111 MRCNS mirrored Gales study 
with MIC90 of 0.5 µg/mL for both groups (Frische et al 
2004). In a larger study of 3574 CNS, Sader et al found 
tigecycline exhibited excellent activity against blood stream 
pathogens (Sader et al 2005). Again the demonstrated MIC90 
was 0.5 µg/mL for CNS and for S. aureus. Data supporting 
this level of activity were also derived in another study 
comparing the activity of a new quinolone, DX-619, with 
other Gram-positive agents (Bogdanovich et al 2005b).
The MIC90 of tigecycline for 61 MRCNS and 67 MSCNS was 
0.5 µg/mL. DX-619 comparatively had an MIC90 0.06 µg/mL. 
In another study, limited number of glycopeptide-intermediate 
susceptible isolated of CNS (22) have been studied for tigecy-
cline and daptomycin susceptibility. In one small set of 8 S. 
epidermidis isolates and 4 S. haemolyticus isolates, the MIC 
was again 0.5 µg/mL for tigecycline, 2.0 µg/mL for arbekacin 
and 1.0 µg/mL for daptomycin (LaPlante and Rybak 2004). 
The minimum bactericidal concentration (MBC):MIC ratio 
was 4 (no speciﬁ  cs given). Time-kill experiments for tetra-
cycline at 4 times the MIC against glycopeptide-intermediate 
S. epidermidis revealed similar killing to daptomycin but 
signiﬁ  cantly more activity than vancomycin at 24 hours. 
Thus, as a tetracycline derivative, tigecycline is surprisingly 
active against susceptible and resistant CNS and has some 
bactericidal effect.
Daptomycin
Daptomycin, an older cyclic glycopeptide that had been 
studied for several decades, was recently brought back to 
clinical life. It made its clinical debut in 2003 for approved 
use in skin and soft tissue infection and has been shown 
recently to be clinically non-inferior to vancomycin in clini-
cal trials of staphylococcal bacteremia (Fowler et al 2006). 
Daptomycin probably has several mechanisms of action 
that involve perturbation of calcium-dependent channels to 
disrupt the cytoplasmic membrane, perhaps ﬁ  rst by altering 
the membrane potential (Silverman et al 2001; Friedman et al 
2006). One of the largest studies of daptomycin-CNS interac-
tions consisted of 1126 CNS (as veriﬁ  ed by Vitek coagulase 
testing) taken from 6,973 gram-positive isolates collected 
from patient specimens at 50 hospitals distributed throughout 
the nine US Bureau of the Census regions (Critchley et al 
2003). Daptomycin was consistently active with an MIC 
range of 0.015–2.0 µg/mL and an MIC90 of 0.5 µg/mL. 
Daptomycin and quinupristin/dalfopristin were the most 
active agents seen in this analysis. As an anti-staphylococcal 
agent, daptomycin may have other advantages like a very low 
spontaneous resistance rates seen during serial passage, and 
the fact that resistant mutants had lower virulence in an animal 
model (Silverman et al 2001). When daptomycin was tested 
for in vitro activity in Mueller-Hinton broth supplemented 
with 50 mg of calcium per liter, MICs were about 4-fold 
lower (Petersen et al 2002). In a comparative study against 
tigecycline, and other Gram-positive agents, the MIC90 of 
daptomycin and tigecycline for MSCNS was 0.25 µg/mL 
and 0.5 µg/mL respectively but was 8- and 2-fold higher 
for MRCNS, respectively. In comparison, the MIC rose 
multifold for other agents like erythromycin, levoﬂ  oxacin, 
and teicoplanin. Resistance to daptomycin has been shown 
in the laboratory with serial passage. Elegant experiments 
of genome comparison revealed that the non-susceptible 
mutants were altered in MprF, a lysylphosphatidylglycerol 
synthetase (Silverman et al 2006).
New ﬂ  uoroquinolones
Several new quinolones have excellent activity against CNS. 
As stated above (see daptomycin), a des-F(6)-quinolone, 
DX-619 was compared to 6 other quinolones. For strains 
that had an MIC90 of 16.0 µg/mL, the DX-619 MIC90 was 
0.125 µg/mL, one tube lower than another new quinolone 
agent, sitaﬂ  oxacin (Bogdanovich et al 2005b). Interestingly, 
killing for DX-619 of a vancomycin-nonsusceptible CNS was 
complete at 4 × MIC and log4 at 12 hours for 2 × MIC. Of 
the currently used ﬂ  uoroquinolones, moxiﬂ  oxacin is prob-
ably the most frequently used. Its MIC90 for MSCNS was 1.0 
µg/mL and for MRCNS was MSCNS was 4.0 µg/mL.
New cephalosporins
Historically, β-lactam antibiotics have produced excellent 
results against methicillin-susceptibile staphylococci. Pro-
duction of aberrant penicillin-binding proteins like PBP-2A 
bypass the effect of β-lactams. Thus, there has been a search 
to ﬁ  nd β-lactams that themselves bind to PBP-2A and thus 
render strains susceptible. Ceftobiprole is one of a new group Therapeutics and Clinical Risk Management 2007:3(6) 1149
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of cephalosporins that are active against methicillin-resistant 
staphylococci. MRSA are susceptible to ceftobiprole at an 
MIC50/MIC90 of 2/2 and MRCNS are similarly susceptible 
with a range of 0.125–4 µg/mL (Bogdanovich et al 2005a). 
Ceftobiprole also demonstrates excellent time-kill kinetics 
and in S. aureus a good post-antibiotic effect (PAE) at MIC 
and sub-MIC concentrations (Pankuch and Applebaum 
2006). In a study of isolates from diabetic foot infections, 
staphylococci were speciated and had excellent ceftibiprole 
MIC90 values (µg/mL): methicillin-susceptible S. aureus 
(MSSA), 0.5; MRSA 1.0; S. epidermidis 1.0; S. haemolyticus 
2.0, and S. ludgenensis 0.5.
New glycopeptides
Several derivatives of vancomycin have been developed and 
brought to clinical trials. Telavancin is a rapidly bactericidal 
lipoglycopeptide with excellent staphylococcal activity. In 
a study of telavancin versus standard therapy for treatment 
of skin and soft tissue infection, CNS caused 13 of 122 
staphylococcal infections (Stryjewski et al 2006). The MIC90 
for telavancin was 0.25 µg/mL (0.06–0.25) among CNS iso-
lates that had a MIC90 of 2.0 for oxacillin. Televancin also 
is one of the few newer agents to exhibit activity in bioﬁ  lms 
(Gander et al 2005). A 3-log decrease in 2 CNS isolates was 
demonstrated in a so-called Sorbarod bioﬁ  lm model.
Dalbavancin is another lipoglycopeptide that inhibits 
cell-wall synthesis. In a British study of 92 isolates from 60 
hospital laboratories, 100% of the isolates were inhibited by 
1 µg/mL of drug (Mushtaq et al 2004). The E-test MIC correla-
tion was excellent with broth dilution but less correlation with 
agar dilution methodology (Fritsche et al 2006). In another
study of dalbavancin compared to other agents including 
oritavancin, an experimental glycopeptide, dalbavancin 
had exceptional activity at the MIC90 level (0.06 µg/mL) for 
both MSCNS and MRCNS (King et al 2004). In that study, 
ortivancin had an MIC90 of 2.0 µg/mL and 4.0 µg/mL for 
MSCNS and MRCNS. Interestingly, dalbavancin has a very 
long half-life (7.5 days) that, when marketed, will challenge 
prescribers who are used to much shorter dosing intervals.
Other agents
Other agents are on the Gram-positive therapy horizon, but 
very few have shown enough promise to come to clinical 
trials. One agent, API-1252, from a group called enoyl-acyl 
carrier protein reductases, has shown excellent antistaphy-
lococcal activity. The MICs for S. epidermidis isolates 
from Canada to API-1252 were excellent, with MIC90 for 
methicillin-suscetible S. epidermidis (MSSE) and MRSE of 
0.06 and 0.03 µg/mL respectively, only slightly higher than 
the MIC90s for S. aureus (Karlowsky et al 2007). A second 
group worth mentioning are the acyldepsipeptides (ADEPs) 
which have a unique mechanism of action and are quite 
active against Gram-positive bacteria. ADEPs activate the 
protease function of ClpP proteins to cause a dysregulation 
of proteolysis (Brötz-Osterhelt et al 2005). The MIC50 for 
S. aureus of one ADEP, is as low as 0.05 µg/mL, but data 
for CNS have yet to be published.
The effect of staphylococcal bioﬁ  lm 
on antimicrobial susceptibility
Bioﬁ  lms consists of a complex extracellular matrix that can 
have profound effects on the ability of antimicrobials to 
inhibit and kill bacteria and fungi. Bioﬁ  lms are extremely 
common in infections due to CNS, bacteria that have special 
sets of genes that regulate and determine cell-wall associ-
ated adhesion and bioﬁ  lm production (Mack et al 2006). 
The regulation of bioﬁ  lm production for most staphylococci 
involves complex schemes (agr, sar, sigB) that result in sets 
of genes being turned on and off depending on the current 
cellular environment. Bioﬁ  lm regulation involves up and 
down regulation of genes that mediate information storage, 
cellular processes and signaling, metabolism and other func-
tions (Yao et al 2006).
It has been known several years that bioﬁ  lms interact 
with antimicrobials (Khardori et al 1991). Early work 
suggested that subtherapeutic levels of certain agents like 
fluoroquinolones and glycopeptides would not prevent 
attachment of bacteria but that β-lactam agents and vanco-
mycin could inhibit aggregative activity (Rupp and Hamer 
1998). The mechanism of bioﬁ  lm-associated antimicrobial 
resistance is likely multifactorial. Unlike other methods to 
test antimicrobial susceptibility, methods that address bioﬁ  lm 
susceptibility to antimicrobial agents have been needed to 
deﬁ  ne fully the inﬂ  uence of bioﬁ  lm on susceptibility (Patel 
2005). To that end, very recent work comparing planktonic 
bacteria to bioﬁ  lm-grown ones has shown large differences 
in susceptibility. Almost all single agents studied (linezolid, 
cefazolin, oxacillin, vancomycin, gentamicin, azithromycin, 
ciproﬂ  oxacin and fusidic acid) had a marked increase in the 
MBC versus the MIC using what is called a modiﬁ  cation of 
the Calgary Bioﬁ  lm Device (Saginur et al 2006). Rifampin 
alone had some predictable equivalence between the MIC 
and the MBC. For S. epidermidis isolates, certain combina-
tions, almost always containing rifampin, were bactericidal 
against 90% of bioﬁ  lms (examples rifampin/vancomycin/
gentamicin; rifampicin/ciprofloxacin/fusidic acid), but Therapeutics and Clinical Risk Management 2007:3(6) 1150
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a smaller number of antibiotic combinations were active 
against bioﬁ  lm-grown bacteria than against planktonic bac-
teria. Strains of S. lugdenensis in bioﬁ  lm have been shown to 
be particularly susceptible to moxiﬂ  oxacin, suggesting that 
some ﬂ  uoroquinolones do have good bioﬁ  lm activity (Frank 
et al 2007). In the same model, vancomycin was shown to 
be non-bactericidal, thus suggesting that bioﬁ  lm contributes 
to the phenomenon of tolerance or lack of killing in certain 
glycopeptides.
The effects of antimicrobials seem to be different at the 
time of adherence versus the later stage of mature bioﬁ  lm 
formation. In a study to test interaction of speciﬁ  c agents with 
bioﬁ  lm, dicloxacillin was more active at both stages than 
cefazolin and vancomycin. Finally, bioﬁ  lm susceptibility 
may be staphylococcal species speciﬁ  c (Cerca et al 2005). An 
Argentine study looked at 5 CNS species and found that of 
88 bioﬁ  lm producing strains, resistance to 2 or more agents 
was seen in 29% of S. haemolyticus, 24% of S. saprophyticus, 
and 20% of S. epidermidis (Gaudioso de Allori et al 2006). 
Such work implies that rapid evaluation of bioﬁ  lm-associated 
resistance should be integrated into clinical consideration. 
Furthermore, their in vitro ﬁ  ndings can be translated into 
clinically applicable devices.
Tigecycline and N-acetylcysteine have been embedded 
into vascular catheters. Such combinations are not only 
inhibitory of bioﬁ  lm growth in vitro but also act synergisti-
cally against MRSA and MRSE (Aslam et al 2007).
Concluding remarks
Coagulase negative staphylococci comprise many species 
which have become increasing pathogenic to man by virtue 
of a changing host of demographics. CNS are relatively 
more resistant than their S. aureus counterparts but have 
fewer virulence factors. They do have a penchant for forming 
bioﬁ  lms on device materials and devitalized tissue, making 
bioﬁ  lm-associated CNS more resistant to penetration by anti-
microbial agents. There are now good methods to show that 
bioﬁ  lms markedly increase the inhibitory concentration of 
standard antistaphylococcal agents. Hospital CNS have broad 
spectrum resistance and usually carry SCCmec cassettes that 
make their host resistant not only to β-lactam but a wide array 
of currently available antimicrobials. There are several newly 
marketed agents including linezolid, tigecycline, and dap-
tomycin that have excellent activity against CNS including 
one species that is almost always pathogenic, S. lugdenesis. 
Other new, non-marketed agents including variations on 
vancomycin and new peptide agents show promise in vitro. 
Like their forebearers, however, there is always the spectre 
of evolving resistance, and only time will determine how 
rapidly resistance does emerge in the clinical arena.
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